drugset / Trial / NCT02142790
Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a open-label study in patients with metastatic breast cancer to evaluate the antitumor activity and safety of weekly dose-dense paclitaxel liposome injection compared to 3-weekly regimen.
Timeline
- Start
- 2014-05
- Primary completion
- 2016-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |